CLOU064C12301 - A randomized double-blind double-dummy parallel-group study comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis followed by extended treatment with open-label remibrutinib

Brief description of study

The main purpose of the study is to find out if patients treated with remibrutinib may experience fewer multiple sclerosis (MS) relapses (also called clinical attacks, exacerbations or flare ups) than patients treated with teriflunomide (also known as Aubagio^®). Teriflunomide is an approved medication for the treatment of relapsing MS.

Clinical Study Identifier: s23-01228

ClinicalTrials.gov Identifier: NCT05147220

Principal Investigator: Josef Maxwell Gutman.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies